Competitive dynamics matter, and often sooner than investors might expect. Eli Lilly's (NYSE: LLY) chief executive officer recently disclosed that the big pharma is positioned to cut off a potential driver of revenue growth for Hims & Hers Health (NYSE: HIMS), and that it will chalk up some growth itself along the way.

Here's what's happening, and how it affects the case for an investment in each company.

Weight loss drugs are wildly popular these days. Eli Lilly's anti-obesity drug Zepbound brought in more than $1.2 billion in sales during the second quarter alone, and it hasn't even been on the market for a whole year yet. There's also ongoing research and development (R&D) work, and a handful of clinical trials attempting to increase the set of conditions that Zepbound is approved to treat.

Continue reading

Source Fool.com